The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Role of Whole Body FDG-PET in the Diagnosis of Hidden Distant Metastasis before Liver Transplantation in Patients with Primary Liver Cancer

고식적 검사로 간외 전이를 진단하지 못한 원발성 간암 환자에서 간이식 전에 시행한 전신 FDG-PET의 역할

  • Lee, Won-Woo (Department of Nuclear Medicine Ulsan University of College of Medicine, Asan Medical Center) ;
  • Ryu, Jin-Sook (Department of Nuclear Medicine Ulsan University of College of Medicine, Asan Medical Center) ;
  • Yang, You-Jung (Department of Nuclear Medicine Ulsan University of College of Medicine, Asan Medical Center) ;
  • Kim, Jae-Seung (Department of Nuclear Medicine Ulsan University of College of Medicine, Asan Medical Center) ;
  • Yeo, Jeong-Seok (Department of Nuclear Medicine Ulsan University of College of Medicine, Asan Medical Center) ;
  • Moon, Dae-Hyuk (Department of Nuclear Medicine Ulsan University of College of Medicine, Asan Medical Center) ;
  • Lee, Sung-Gyu (Department of Surgery, Ulsan University of College of Medicine, Asan Medical Center)
  • 이원우 (울산대학교 의과대학 서울아산병원 핵의학과) ;
  • 류진숙 (울산대학교 의과대학 서울아산병원 핵의학과) ;
  • 양유정 (울산대학교 의과대학 서울아산병원 핵의학과) ;
  • 김재승 (울산대학교 의과대학 서울아산병원 핵의학과) ;
  • 여정석 (울산대학교 의과대학 서울아산병원 핵의학과) ;
  • 문대혁 (울산대학교 의과대학 서울아산병원 핵의학과) ;
  • 이승규 (울산대학교 의과대학 서울아산병원 외과)
  • Published : 2002.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Liver transplantation (LT), one of the therapeutic options of primary liver cancer has been suffering from recurrence caused by metastasis in 8-54% of patients. This study was performed to investigate whether FDG-PET is useful for detecting hidden metastasis in LT candidates. Materials and Methods: Twenty-six patients (male:female=23:3, mean age 55.7 years) underwent FDG-PET. Their previous conventional diagnostic studies (CDS) like abdomen US and CT, chest x-ray and CT, and bone scan were negative (n=22) or equivocal (n=4) for metastasis. Positive FDG-PET findings were confirmed by biopsy or clinical follow-up. Results: Among 4 patients with equivocal metastatic lesions on CDS, 3 had 6 hypermetabolic lesions on FDG-PET, which were confirmed as metastasis and subsequently LTs were cancelled. Of these, 5 lesions were initially negative on CDS. Remained 1 patient underwent LT with a negative FDG-PET result. Among 22 patients without metastasis on CDS, 5 had 7 hypermetabolic lesions on FDG-PET. One of these patients proved to have 2 metastatic lesions, and LT was cancelled. The other 4 patients had S hypermetabolic lesions on FDG-PET, which were confirmed as benign lesions, and 3 patients of them underwent LT. In summary, FDG-PET was useful in avoiding 4 unwarranted LT by detecting unsuspected metastatic lesions on CDS. A total of 17 patients underwent LT. In comparison with pathology, the sensitivity and specificity of FDG-PET for detecting viable primary liver cancer were 55.6% (5/9) and 87.5% (7/8), respectively. Conclusion: FDG-PET can detect additional hidden metastasis and contribute to reducing unwarranted LT in the patients with primary liver cancer.

목적: 원발성 간암의 치료를 위해 간이식이 시행되고 있으나, 8-54%의 환자에서는 이식 후 원격 전이로 인한 재발이 보고 되고 있다. 이 연구는 간이식 예정인 원발성 간암 환자들에서 고식적인 검사로 진단하지 못한 간외 전이 진단에 있어서 FDG-PET의 유용성을 평가하고자 시행되었다. 대상 및 방법: 2001년 8월 이후 본원에서 간이식을 계획하고 전신 FDG-PET을 시행한 환자 중, FDG-PET 검사 이전에 복부 초음파와 CT, 흉부 x선 검사와 CT, 골스캔 등의 고식적인 검사를 시행하여 전이의 증거가 없거나(n=22), 애매한 이상 소견이 있었던(n=4) 원발성 간암 환자 26명(남:여=23:3, 평균 나이 55.7세)을 조사하였다. FDG-PET에서 양성을 보인 결과는 조직검사나 임상적인 추적 검사로 전이 여부를 확인하였다. 결과: 고식적 검사에서 애매한 이상 소견이 있었던 환자 4명 중 3명의 6개 병변이 FDG-PET에서 국소 대사 항진을 보였고, 전이로 확인되어 간이식을 시행하지 않았다. 이 중 5 병변들은 의심되지 않았던 부위에서 새로 발견된 것이었다. 다른 1명은 PET에서 음성 소견으로 간이식을 시행하였다. 고식적인 검사에서 전이를 의심할 만한 소견이 없었던 22명 중에서는 5명의 환자에서 7개의 간외 국소 대사항진 병변들이 FDG-PET에서 발견되었는데, 이들중 1명은 2개의 전이 병변이 확인되어 간이식을 시행하지 않았다. 다른 4명의 환자들에서 보인 5개의 국소 대사항진 병변들은 양성병변으로 확인되었고 이 중 3명은 간이식을 시행하였다. 요약하면, FDG-PET으로 4명의 환자에서 고식적인 검사로 찾지 못하던 전이 병변을 찾아 불필요한 간이식을 피할 수 있었다. 모두 17명에서 간이식이 시행되었다. 간의 조직 검사 소견과 비교하였을 때 생존 원발성 간암을 진단하는 FDG-PET의 민감도는 55.6% (5/9)이었고, 특이도는 87.5% (7/8)이었다. 결론: FDG-PET 전신 스캔은 간이식 예정인 원발성 간암 환자들에서 이전에 시행한 고식적인 검사들로 진단하지 못한 전이 병소들을 추가로 진단하여 불필요한 간이식 수술을 줄이는데 기여할 수 있었다.

Keywords

References

  1. Befeler AS, Di Bisceglie AM. Hepatocellularcarcinoma: diagnosis and treatment. Gastroen-terology 2002;122:1609-19.
  2. Iwatsuki S, Starzl TE. Role of liver transplantationin the treatment of hepatocellularcarcinoma. Semin Surg Oncol 1993;9:337-40.
  3. Bismuth H, Chiche L, Adam R, Castaing D,Diamond T, Dennison A. Liver resection versustransplantation for hepatocellular carcinoma incirrhotic patients. Ann Surg 1993;218:145-51.
  4. Mazzaferro V, Regalia E, Doci R, Andreola S,Pulvirenti A, Bozzetti F, et al. Liver transplantationfor the treatment of small hepatocellularcarcinomas in patients with cirrhosis. NEngl J Med 1996;334:693-9.
  5. Ismail T, Angrisani L, Gunson BK, HubscherSG, Buckels JA, Neuberger JM, et al. Primaryhepatic malignancy: the role of liver transplantation.Br J Surg 1990;77:983-7.
  6. Trojan J, Schroeder 0, Raedle J, Baum RP,Herrmann G, Jacobi V, et al. Fluorine-18 FDGpositron emission tomography for imaging ofhepatocellular carcinoma. Am J Gastroenterol1999;94:3314-9.
  7. Wahl RL. Principles and Practice of PositronEmission Tomography. Philadelphia: LippincottWilliams and Wilkins; 2002. p. 100-10.
  8. Khan MA, Combs CS, Brunt EM, Lowe VJ,Wolverson MK, Solomon H, et al. Positronemission tomography scanning in the evaluationof hepatocellular carcinoma. J Hepatol 2000;32:792-7.
  9. Beets G, Penninckx F, Schiepers C, Filez L,Mortelmans L, Kerremans R, et al. Clinicalvalue of whole-body positron emission tomographywith [$^18$F]fluorodeoxyglucose in recurrentcolorectal cancer. Br J Surg 1994;81:1666-70.
  10. Lai DT, Fulham M, Stephen MS, Chu KM,Solomon M, Thompson JF, et al. The role ofwhole-body positron emission tomography withC8F]fluorodeoxyglucose in identifying operablecolorectal cancer metastases to the liver. Arch Surg 1996;131:703-7.
  11. Ruers TJ, Langenhoff BS, Neeleman N, JagerGJ, Strijk S, Wobbes T, et al. Value of positronemission tomography with [F-18]fluorodeoxyglucosein patients with colorectal liver metastases:a prospective study. J Clin Oncol2002;20:388-95.
  12. Kato T, Tsukamoto E, Kuge Y, Katoh C,Nambu T, Nobuta A, et al. Clinical role of(18)F-FDG PET for initial staging of patientswith extrahepatic bile duct cancer. Eur J NuclMed Mol Imaging 2002;29:1047-54.
  13. Hong HG. The 10th anniversary of livertransplantation in Asan Medical Center. JoongangIlbo. Seoul: 12 Nov. 2002; pp.E23.
  14. Torizuka T, Tamaki N, Inokuma T, Magata Y,Yonekura Y, Tanaka A, et al. Value offluorine-18-FDG-PET to monitor hepatocellularcarcinoma after interventional therapy. J NuclMed 1994;35:1965-9.
  15. Harnois DM, Steers J, Andrews JC, Rubin JC,Pitot HC, Burgart L, et al. Preoperative hepaticartery chemoembolization followed by orthotopicliver transplantation for hepatocellular carcinoma.Liver Transpl Surg 1999;5: 192-9.
  16. Ho C, Yeung DW. llC-Acetate PET imagingcharacteristics in hepatocellular carcinoma. JNucl Med (Suppl) 2002; 43:24. (Abstract number84).
  17. Llovet JM, Bruix J, Fuster J, Castells A,Garcia-Valdecasas JC, Grande L, et al. Livertransplantation for small hepatocellular carcinoma:the tumor-node-metastasis classificationdoes not have prognostic power. Hepatology1998; 27:1572-7.
  18. Shiomi S, Nishiguchi S, Ishizu H, Iwata Y,Sasaki N, Tamori A, et al. Usefulness ofpositron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome inpatients with hepatocellular carcinoma. Am J Gastroenterol 2001;96:1877-80.
  19. Park MS, Kim KW, Yu IS, Kim MI, Yoon SW,Chung KW, et al. Radiologic findings ofgastrointestinal tract involvement in hepatocellularcarcinoma. J Comput Assist Tomogr 2002;26:95-101.
  20. Kim PN, Kim IY, Lee KS. Intraperitonealseeding from hepatoma. Abdom Imaging 1994;19:309-12.
  21. Kim TK, Han IK, Chung IW, Choi BI, Park JR,Han MC. Intraperitoneal drop metastases fromhepatocellular carcinoma: CT and angiographicfindings. J Comput Assist Tomogr 1996;20:638-42.